Expression of membrane type 1 matrix metalloproteinase in medullary thyroid carcinoma: prognostic implications

Head and Neck

Volumn 32, Issue 1, 2010, Pages 58-67

  Cavalheiro, Beatriz Godoi ^a,b   Junqueira, Consuelo Rodrigues ^b   Brandão, Lenine Garcia ^b  

^a Instituto Brasileiro de Controle do Cancer   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Immunohistochemistry; Medullary carcinoma; Metalloproteases; Prognosis; Thyroid neoplasms

Indexed keywords

MATRIX METALLOPROTEINASE 14; PARAFFIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONVALESCENCE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; THYROID MEDULLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; CARCINOMA, MEDULLARY; CHILD; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 75149189574     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21146     Document Type: Article

References (40)

1. Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg 2003;128:115-123.
2. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984;63:319-342.
3. Tisell LE, Hansson G, Jansson S. Surgical treatment of medullary carcinoma of the thyroid. Horm Metab Res Suppl 1989;21:29-31.
4. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Clin Endocrinol (Oxf) 1998;48:265-273.
5. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma-recommendations for extent of node dissection. Ann Surg 1999;229:880-888.
6. Weber T, Schilling T, Frank-Raue K, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 2001;130:1044-1049.
7. Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Intern Med 2003;253:616-626.
8. Kraiem Z, Korem S. Matrix metalloproteinases and the thyroid. Thyroid 2000;10:1061-1069.
9. Cvejić D, Savin S, Paunovic I, Tatic S, Havelka M. Immunohistochemical localization of matrix metalloproteinase-2 (MMP-2) in medullary thyroid carcinoma. Arch Oncol 2000;8:95-97.
10. Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36:128-137.
11. Vihinen P, Kähä ri VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-166.
12. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003;194:1-11.
13. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 2002;54:255-264.
14. Okada A, Bellocq JP, Rouyer N, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 1995;92:2730-2734.
15. Wu YI, Munshi HG, Snipas SJ, Salvesen GS, Fridman R, Stack MS. Activation-coupled membrane type 1 matrix metalloproteinase membrane trafficking. Biochem J 2007;407:171-177.
16. Kayano K, Shimada T, Shinomiya T, et al. Activation of pro-MMP mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2. J Pathol 2004;202:403-411.
17. Nakamura H, Ueno H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 1999;59:467-473.
18. Hofmann A, Laue S, Rost AK, Scherbaum WA, Aust G. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines. Thyroid 1998;8:203-214.
19. Yeh MW, Rougier JP, Park JW, et al. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer 2006;13:1173-1183.
20. Rosenthal EL, Matrisian LM. Matrix metalloproteinases in head and neck cancer. Head Neck 2006;28:639-648.
21. Scurry WC Jr, Stack BC Jr. Role of metalloproteins in the clinical management of head and neck squamous cell carcinoma. Head Neck 2007;29:1144-1155.
22. Imanish Y, Fujii M, Tokumaru Y, et al. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase 2 in human head and neck squamous cell carcinoma. Hum Pathol 2000;31:895-904.
23. Zedenius J, Ståhle-Bäckdahl M, Enberg U, et al. Stromal fibroblasts adjacent to invasive thyroid tumors: expression of gelatinase A but not stromelysin 3 mRNA. World J Surg 1996;20:101-106.
24. Patel A, Straight AM, Mann H, et al. Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents. J Endocrinol Invest 2002;25:403-408.
25. Baldini E, Toller M, Graziano FM, et al. Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines. Thyroid 2004;14:881-888.
26. Tomita T. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in thyroid C-cells and medullary thyroid carcinomas. Histopathology 1997;31:150-156.
27. Campo E, Merino MJ, Liotta L, Neumann R, Stetler-Stevenson W. Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol 1992;23:1395-1401.
28. Maeta H, Ohgi S, Terada T. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 2001;438:121-128.
29. Dahlman T, Lammerts E, Wik M, et al. Fibrosis in undifferentiated (anaplastic) thyroid carcinomas: evidence for a dual action of tumor cells in collagen type I synthesis. J Pathol 2000;191:376-386.
30. Cavalheiro BG, Junqueira CR, Brandão LG. Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma. Thyroid 2008;18:865-871.
31. Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H. Advances in the management of hereditary medullary thyroid cancer. J Intern Med 2005;257:50-59.
32. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxiodase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:283-286.
33. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-65.
34. Cho Mar K, Eimoto K, Tateyama H, Arai Y, Fujiyoshi Y, Hamaguchi M. Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology 2006;48:286-294.
35. Pellegriti G, Leboulleux S, Baudin E, et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 2003;88:1537-1542.
36. Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 1998;22:562-568.
37. Dralle H, Sheumann GFW, Proye C, et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J Intern Med 1995;238:357-361.
38. Van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990;212: 395-400.
39. Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee EL, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 2003;134:890-899.
40. Franc S, Niccoli-Sire P, Cohen R, et al and the GETC. Complete surgical lymph node resection does not prevent authentic recurrences of medullary carcinoma. Clin Endocrinol (Oxf) 2001;55:403-409.